Drug Profile
Research programme: FPR2 agonists - Bristol-Myers Squibb/kyorin pharmaceutical
Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Kyorin Pharmaceutical
- Developer Bristol-Myers Squibb; Kyorin Pharmaceutical
- Class Heart failure therapies; Small molecules
- Mechanism of Action Formyl peptide receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Heart-failure in Japan
- 03 Sep 2020 Preclinical development is ongoing in Japan (Bristol-Myers Squibb pipeline, August 2020)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Heart-failure in Japan